Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Accumulated Expenses (2016 - 2026)

Champions Oncology has reported Accumulated Expenses over the past 16 years, most recently at $3.3 million for Q1 2026.

  • For Q1 2026, Accumulated Expenses rose 47.6% year-over-year to $3.3 million; the TTM value through Jan 2026 reached $3.3 million, up 47.6%, while the annual FY2025 figure was $2.6 million, 18.33% up from the prior year.
  • Accumulated Expenses for Q1 2026 was $3.3 million at Champions Oncology, up from $2.2 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $3.3 million in Q1 2026 and troughed at $1.7 million in Q4 2022.
  • A 5-year average of $2.2 million and a median of $2.2 million in 2024 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: fell 14.12% in 2025 and later soared 47.6% in 2026.
  • Year by year, Accumulated Expenses stood at $1.7 million in 2022, then rose by 21.14% to $2.0 million in 2023, then grew by 10.48% to $2.2 million in 2024, then decreased by 2.1% to $2.2 million in 2025, then skyrocketed by 52.93% to $3.3 million in 2026.
  • Business Quant data shows Accumulated Expenses for CSBR at $3.3 million in Q1 2026, $2.2 million in Q4 2025, and $1.8 million in Q3 2025.